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A B S T R A C T   
Inflammatory bowel disease (IBD) is a set of immunological disorders which can generate chronic pain and 
fatigue associated with the inflammatory symptoms. The treatment of IBD remains a significant hurdle with 
current therapies being only partially effective or having significant side effects, suggesting that new therapies 
that elicit different modes of action and delivery strategies are required. TGM1 is a TGF-β mimic that was 
discovered from the intestinal helminth parasite Heligmosomoides polygyrus and is thought to be produced by the 
parasite to suppress the intestinal inflammation response to help evade host immunity, making it an ideal 
candidate to be developed as a novel anti-inflammatory bio-therapeutic. Here we utilized the expression system 
of the edible green algae Chlamydomonas reinhardtii in order to recombinantly produce active TGM1 in a form 
that could be ingested. C. reinhardtii robustly expressed TGM1, and the resultant recombinant protein is bio-
logically active as measured by regulatory T cell induction. When delivered orally to mice, the algal expressed 
TGM1 is able to ameliorate weight loss, lymphadenopathy, and disease symptoms in a mouse model of DSS- 
induced colitis, demonstrating the potential of this biologic as a novel treatment of IBD.   
1. Introduction 
Inflammatory Bowel Disease (IBD) is a chronic immunological dis-
order of the gastrointestinal tract that affects millions of people in the 
world (de Souza and Fiocchi, 2016; Kaser et al., 2010). Every year, 
hundreds of thousands of new patients suffer from this disease, with a 
high risk of becoming seriously sick and debilitated, creating an enor-
mous socioeconomic burden (Burisch et al., 2019). The two principal 
types of IBD are Crohn’s disease (CD) (Baumgart and Sandborn, 2012) 
and ulcerative colitis (UC) (Danese and Fiocchi, 2011). While diagnosis 
is well-developed, no curative treatments for these diseases are avail-
able, with surgical resection a last resort. IBD can be triggered by poorly 
understood physiological states, and by numerous environmental factors 
including diet, stress, and infections. Although the detailed mechanism 
of IBD development is unclear, it is well acknowledged that IBD is 
associated with a failure of immune regulatory mechanisms, resulting in 
chronic inflammation and production of pro-inflammatory cytokines, 
leading to tissue destruction and tumorigenesis (Burisch et al., 2019; 
Neurath et al., 2002). 
Key inflammatory cytokines have been targeted for IBD treatment, 
with the most effective therapy found to be antibody against tumor 
necrosis factor (TNF); however, this is not effective for patients with few 
immune cells expressing membrane-bound TNF (Wong et al., 2008). An 
alternative strategy is to deliver recombinant anti-inflammatory cyto-
kines. These include IL-10 (Saraiva et al., 2020), IL-22 (Sugimoto et al., 
2008), IL-27 (McLean et al., 2017) and TGF-β (Ihara et al., 2017), which 
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are produced by mucosal immune cells and/or epithelium, which 
exhibit both potent anti-inflammatory and tissue-repair effects, through 
regulatory T cell generation and enhancing epithelial cell function. 
However, the paracrine manner in which these cytokines act, creates a 
challenge in delivering pharmacologic amounts of these factors only to 
the gastrointestinal mucosa. In animal models, pathology can be sup-
pressed by pre-treatment with anti-inflammatory cytokines such as IL-10 
(Huber et al., 2011), while established disease is ameliorated by oral 
delivery of IL-10-expressing transgenic Lactococcus lactis (Steidler et al., 
2000). In clinical trials, systemic IL-10 administration showed no benefit 
at doses low enough to avoid significant side effects (Buruiana et al., 
2010; Schreiber et al., 2000), and published reports on oral delivery 
have been limited to safety trials in healthy individuals (Braat et al., 
2006). 
TGF-β has wide-ranging effects in immune suppression and wound 
repair (David and Massague, 2018) and plays a prominent role in 
maintaining homeostasis of the mucosal immune system (Ihara et al., 
2017; Konkel and Chen, 2011). In colitis, elevated TGF-β expression 
dampens inflammation, and one therapeutic avenue has been to boost 
TGF-β efficacy by anti-sense RNA abrogation of the Smad7 inhibitor of 
the TGF-β signaling pathway (Monteleone et al., 2015). Transgenic 
Bacteroides ovatus which can be induced to release TGF-β have also been 
shown to downmodulate colitis in mouse models (Hamady et al., 2011). 
An alternative strategy to ameliorate inflammatory bowel diseases 
has emerged from studies with parasitic helminth worms (Weinstock 
and Elliott, 2013). Globally, there is an inverse relationship between the 
prevalence of intestinal helminth parasites and the incidence of IBD 
(Varyani et al., 2017); in mouse models, infections with diverse hel-
minth species can abrogate colitis (Hunter et al., 2005; Leung et al., 
2012; Smith et al., 2007), and deliberate infection of IBD patients has 
been advocated as a new therapy for disease (Summers et al., 2005). One 
species associated with anti-inflammatory effects in vivo, Heli-
gmosomoides polygyrus, has been shown to secrete a potent TGF-β mimic, 
TGM1 (Johnston et al., 2017; Smyth et al., 2018). Parasite TGM1 and 
mammalian TGF-β have no sequence similarity, however TGM1 ligates 
the mammalian TGF-β receptor (TBRII), initiating downstream Smad 
signaling and inducing suppressive Foxp3+ regulatory T cell (Tregs) 
(Cook et al., 2021; White et al., 2021). We are therefore investigating 
whether oral therapy with helminth-derived TGM, rather than live 
infection with helminth parasites, would be the therapy of choice for 
IBD. 
In this study, we tested the idea of producing recombinant TGM1 in 
the edible green algae Chlamydomonas reinhardtii, in order to be able to 
feed TGM1 directly to mice and assess the protein’s action from within 
the gastrointestinal tract, and with the view to developing a bio- 
therapeutic for use in humans to treat a range of gastrointestinal in-
flammatory diseases. Compared to other cell-based expression systems, 
the use of algae as a cellular factory has several benefits, including cost 
effective cultivation under photosynthetic growth, and rapid low cost 
scaling from lab to commercial scale, rendering it orders of magnitude 
less costly than conventional mammalian cell culture technologies 
(Dove, 2002). Additionally, unlike other low-cost cell systems such as 
yeast or bacteria, algae have the cellular machinery in both the endo-
plasmic reticulum (ER) and chloroplast, that are required for assembling 
complex mammalian proteins and antibodies (Gregory et al., 2013; 
Patra et al., 2015; Ravi et al., 2018; Tran et al., 2013). We have previ-
ously demonstrated that C. reinhardtii can be engineered to express a 
number of bioactive proteins (Gimpel et al., 2015; Rasala et al., 2012; 
Tran et al., 2009) and that the biomass can be safely consumed orally in 
mice and humans (Fields et al., 2020), and shown to be able to deliver 
recombinant protein cargoes to the intestinal tract of mice (Barrera 
et al., 2015). We have now expressed an active novel anti-inflammatory 
cytokine TGM1 in C. reinhardtii and further show that the algal TGM1 
when given orally is able to regulate immune cells and protect mice from 
DSS colitis weight loss. 
2. Materials and methods 
2.1. Plasmid construction for recombinant TGM1 protein expression 
To express recombinant TGM1 using C. reinhardtii, we designed a 
codon-optimized TGM1 construct with a FLAG tag based on the previ-
ously described secretion vector pBR9 (Rasala et al., 2013), to maximize 
protein expression (Fig. 1 A). The N-terminal ars1 algae signal peptide 
allows for the secretion of TGM1 into the medium. Additionally, the AR1 
promoter and rbcs 3’ UTR ensure that the transformed construct locates 
to the nucleus and that protein is continuously expressed under light 
conditions. pBR9 also encodes the Bleomycin selection gene Ble2A to 
isolate transformed algae. As previous work had shown that domains 
1–3 of TGM1 were sufficient for biological activity (Smyth et al., 2018), 
a similar construct was made to also express truncated TGM1 (TrTGM1). 
The sequence for mature TGM1 (or TrTGM1) was adapted to the 
nuclear codon usage of C. reinhardtii according to the Kazusa DNA 
Research Institute’s database (http://www.kazusa.or.jp/codon/cg 
i-bin/showcodon.cgi?species=3055) as previously described (Rasala 
et al., 2013), and is presented in Supplementary Fig. 1. Synthetic genes 
plus an 8-aa FLAG tag (DYKDDDDK) were synthesized by Genewiz and 
cloned into pBR9 as XhoI/BamHI fragments. The resultant constructs, 
named pBR9-TGM1 and pBR9-TrTGM1, were transformed into wild type 
CC-1690 C. reinhardtii by electroporation with high-level expressing 
transformants being selected by dot-blot screening for further 
large-scale expression and purification (Fig. 1 B). 
2.2. C. reinhardtii transformation and screening 
2.2.1. Transformation 
C. reinhardtii wild type strain CC-1690 was used for secreted TGM1 
protein expression. C. reinhardtii was grown in tris-acetate-phosphate 
(TAP) (Gorman and Levine, 1965) liquid medium at room tempera-
ture (RT) on a rotary shaker set at 100 rpm, under constant light in-
tensity (100 µmol photons m−2 s−1) to a concentration of approximately 
1 × 106 cells⋅mL-1. Cells were harvested by centrifugation (2000 g) and 
then resuspended with MAX Efficiency® Transformation Reagent for 
Algae (Thermo Fisher Scientific Inc., MA, Cat #A24229). One million 
cells in 300 µL transformation reagent were mixed with 5 µg of linear-
ized plasmid digested with KpnI and incubated on ice for 30 min. The 
cell suspension was placed into a prechilled disposable electroporation 
cuvette with a 4-mm gap (Bio-Rad Labs., Hercules, CA, Cat #1652081) 
for 5 min on ice. A BioRad Gene Pulser Xcell with the following settings 
(Voltage 500 V, Capacity 50 µF and Resistance 800 Ω) was used for 
electroporation. Electroporated C. reinhardtii cells were recovered with 
10 mL of 20 mM sucrose in TAP medium for 24 h, and then plated on 
TAP agar plates with 15 µg⋅mL-1 Zeocin and incubated at RT for 10 days. 
2.2.2. Dot blot screening 
A dot blot assay (Rupprecht et al., 2010) was modified to screen 
transformed colonies in order to select clones with higher TGM1 
secretion yields. Nitrocellulose membranes, 7 × 7 cm, were marked 
with a grid of 100 small squares and placed on a 10 cm diameter Fish-
erbrand™ Petri Dishes (Fisher Scientific, Cat #FB0875713) of TAP agar. 
One hundred of the transformed of the colonies were randomly picked 
and patched onto two replicate nitrocellulose membranes in a grid for-
mation and the incubated under light at RT for three days. After three 
days, all colonies were washed off one of the replicate nitrocellulose 
membranes with TBST (Tris-buffered saline plus 0.05% Tween-20). The 
nitrocellulose membrane was blocked with 5% non-fat milk powder in 
TBST for 1 h and then incubated with Monoclonal ANTI-FLAG® 
M2-Alkaline Phosphatase antibody (Sigma-Aldrich, St. Louis, MO, USA, 
Cat #A9469; final dilution 1:5000) for 1 h. The membrane was then 
washed with TBST 3 × 5 min and visualized in nitro-blue tetrazolium 
(NBT) / 5-bromo-4-chloro-3’-indolyphosphate p-toluidine salt (BCIP) 
(Sigma-Aldrich, St. Louis, MO, USA, Cat #B5655) added directly to the 
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membrane for development. Developed dot blot intensity was correlated 
with yield of secreted TGM1 and the transgenic clones with highest 
protein secretion were recovered from the second replicate membrane 
for further protein expression and purification. 
2.2.3. Western blot and Coomassie Blue staining 
Transgenic TGM1 strains were grown in liquid medium TAP. Cells 
were cultured at RT, on rotary shaker set at 100 rpm, under constant 
light intensity (100 µmol photons m−2 s−1), to a cell concentration 
around 6 × 106 cells mL-1. Supernatants were harvested by centrifuging 
cells at 7800 g, added to 4 volumes of prechilled acetone (Sigma-Aldrich 
Cat # 650501) and incubated at 4 ◦C overnight. Precipitated protein 
pellets were obtained by centrifuging acetone-treated supernatants at 
17,000 g for 10 min at 4 ◦C and air dried for 5 min. ddH2O was used to 
resuspend the dried protein pellet and 4X Laemmli sample buffer (Bio-
Rad, Cat # 1610747) with 10% β-mercaptoethanol (Sigma-Aldrich Cat 
# M6250) was then added as 1:4 ratio (sample buffer: sample). Reduced 
samples were heated at 65 ◦C for 10 min and loaded onto 10% Mini- 
PROTEAN® TGX™ Precast Protein Gels (BioRad, Cat # 4561036). The 
molecular weight marker used was AccuRuler RGB Plus Prestained 
Protein Marker (Biopioneering, Cat # PM-001). A voltage of 120 was 
applied and the gels were run for 1 h. One gel was stained in Coomassie 
SimplyBlue™ SafeStain (Thermos Fisher Scientific, Cat # LC6060) for 
1 h, followed by destaining in ddH2O. Another gel was transferred to 
nitrocellulose membrane (BioRad, Cat # 1620112). The membrane was 
blocked with 5% non-fat milk in TBST for 1 h at RT. The membrane was 
probed with Monoclonal ANTI-FLAG® M2-Alkaline Phosphatase anti-
body as described above for 1 h and then washed with TBST 3 × 5 min; 
NBT/BCIP developer tablet (Sigma FAST B5655, St. Louis, MO, USA) 
was dissolved in 50 mL ddH2O and used to visualize the protein band on 
the membrane. 
2.3. C. reinhardtii bulk expression conditions for algal TGM1 
Transgenic TGM1 and TrTGM1 strains were grown with 1 L TAP 
liquid medium in 2 L Erlenmeyer flasks. These culture flasks were 
maintained at RT on a rotary shaker set at 100 rpm, under constant light 
intensity (100 µmol photons m−2 s−1), to a cell concentration of 
approximately 6 × 106 cells mL−1. Supernatants were harvested by 
centrifugation (7800 g) and then filtered by Whatman Grade GF/A Fine 
Retention Filter paper (GE Healthcare Life Science, 1820-021). Filtered 
supernatant was further processed to obtain recombinant protein with 
either FLAG affinity purification or ammonium sulfate precipitation 
(Fig. 1 C, D). Wild type algae strain CC-1690 was grown under the same 
conditions and treated in the same manner as the transgenic TGM1 
strain and used as an algal protein control for assays and in vivo mouse 
models. 
2.4. Purification of secreted algal TGM1 from C. reinhardtii 
2.4.1. Anti-FLAG resin purification of algal TGM1 and TrTGM1 
FLAG affinity chromatography was used to purify TGM1 and 
TrTGM1 for mass spectrometry, glycosylation analysis and in vitro cell- 
based assays for activity. Briefly, 1 mL of anti-FLAG affinity gel 
(Sigma-Aldrich Cat # A4596) was equilibrated in lysis buffer (50 mM 
Tris, 150 mM NaCl, 1 mM EDTA, pH 7.4) with 5 column volumes (CV) 
and then loaded with 2 L filtered supernatant. The resin was washed 
with 5 CV of lysis buffer and then eluted with 6 sequential 1 CV of 
elution buffer (100 mM Glycine, 400 mM NaCl, pH 3.5). The pH of the 
eluate was immediately adjusted to pH 7.5 with 50 µL 1 M Tris-HCL. For 
quantification, 10 µL of purified TGM1 and TrTGM1, and 50 ng 45-kDa 
recombinant Posi-Tag Epitope Tag Protein containing the epitope FLAG 
tag(BioLegend, Cat #931301) were loaded to SDS-PAGE gel and 
analyzed by Western blot with anti-FLAG antibody; band intensities 
were then quantified by Image Studio Lite(LI-COR Biosciences, Lincoln, 
NE, USA). The FLAG-purified TGM1 was then sent for mass spectrom-
etry, glycosylation analysis and both FLAG-purified TGM1 and TrTGM1 
were used for in vitro cell-based activity assays. 
2.4.2. Ammonium sulfate precipitated TGM1 and wild type algal proteins 
for in vivo mouse models 
For larger scale isolation of TGM1, ammonium sulfate was added 
slowly to filtered algae supernatant to a final salt concentration of 
250 g⋅L-1. The mixture was incubated at 4 ◦C overnight and then 
centrifuged at 7800 g to harvest the precipitated protein pellet. The 
precipitated protein pellet was resuspended in DPBS (Thermo Fisher, 
Cat #14190144) and dialyzed twice with Thermo Scientific™ Snake-
Skin™ Dialysis Tubing (10 K MWCO, Thermo Fisher, Cat # 68100) 
overnight in DPBS at 4 ◦C. To protect proteins from aggregation and 
increase their stability sterile glycerol was added into the samples with a 
final concentration of 2% (v/v). For quantification, 2 µL of resuspended 
protein supernatant and 150 ng of recombinant Posi-Tag Epitope Tag 
Protein as a FLAG standard were analyzed by SDS-PAGE gel and protein 
band pixel intensities were quantified by Image Studio Lite. Total pro-
tein concentrations in precipitated supernatant were quantified by 
Pierce™ BCA Protein Assay Kit (Thermo Fisher, Cat #23225) at 562 nm 
against BSA standards. 
Wild-type (WT) algal proteins used as a control in assays and mouse 
models was CC-1690 C. reinhardtii WT filtered supernatant processed 
with the same procedure as above and the final concentration of these 
supernatants were measured by Pierce™ BCA Protein Assay Kit. 
2.5. Glycosylation analysis and mass spectrometry of FLAG-purified algal 
TGM1 
For glycosylation analysis, 1 µg FLAG-affinity purified algal TGM1 
samples were digested with either 5 U of PNGase F (NEB, Cat # P0704S) 
or 5 U EndoH (NEB, Cat # P0702S) at 37 ◦C for one hour. Digested 
proteins were heat inactivated at 65 ◦C for 10 min and analyzed by SDS- 
PAGE. For more detailed investigation, untreated protein samples in 
50 mM ammonium bicarbonate, 0.1% w/v ProteaseMax surfactant were 
reduced and alkylated prior to proteolytic digestion with trypsin at a 
ratio of 1:50. Proteolysis was stopped, and surfactant hydrolyzed by the 
addition of 0.5% trifluoroacetic acid (TFA). Sample desalting was per-
formed using HyperSep Hypercarb solid-phase extraction tips followed 
by drying by vacuum centrifugation (Eppendorf). 
Liquid Chromatography with tandem mass spectrometry (LC MS/ 
MS) was performed by nano-flow liquid chromatography (U3000 
Fig. 1. Expression of Heligmosomoides polygyrus TGM1 in Chlamydomonas reinhardtii. A. Construct design comprising pAR1, a constitutive promoter (670 bp) used for 
high level protein expression in Chlamydomonas; Ble2A, an antibiotic resistance gene; Ars1 SP, a 30-aa secretion signal peptide (orange filled box) codon-optimized 
mature 5-domain TGM1 (blue boxes), or truncated TGM1 (TrTGM1, lacking Domains 4 and 5, hatched blue); FLAG tag (purple); and rbcs 3’ UTR (246 bp), a robust 
element to maintain algal mRNA stability. The sequence encoding the expressed protein was inserted into pBR9 through XhoI and BamHI restriction sites as indicated, 
and is given in full in Supplementary Fig. S1. B. Schematic of experimental approach including dot blot screening to select high expressing clones, and purification of 
TGM1 by affinity chromatography (C) for in vitro bioassays (see Fig. 2) or ammonium sulfate precipitation for in vivo administration (see Fig. 3 and 4). C. Western blot 
of anti-FLAG antibody affinity-purified TGM1 and TrTGM1, stained with Monoclonal ANTI-FLAG® M2-Alkaline Phosphatase antibody. Ten µL of each purified 
protein sample(TGM1 and TrTGM1) and 50 ng 45-kDa Recombinant Posi-Tag Epitope Tag Protein containing the epitope FLAG tag were loaded onto a SDS-PAGE gel. 
Marker protein molecular weights are indicated. D. Coomassie Blue stained (left hand panel) and anti-FLAG Western blot (right hand panel) of ammonium sulfate- 
precipitated TGM1. Two µL of TGM1 sample and 150 ng Recombinant Posi-Tag Epitope Tag Protein were loaded onto a SDS-PAGE gel. Marker protein molecular 
weights are indicated. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) 
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RSLCnano) coupled to a hybrid quadrupole-orbitrap mass spectrometer 
(Q Exactive HF). Peptides were separated on an Easy-Spray C18 column 
(75 µm × 50 cm) using a 2-step gradient from 97% solvent A (0.1% 
formic acid in water) to 10% solvent B (0.08% formic acid in 80% 
acetonitrile) over 5 min then 10–50% B over 75 min at 300 nL.min-1. 
Mass spectra were acquired with automated data-dependent switching 
between full-MS and tandem MS/MS scans using stepped collision en-
ergy. Data analysis was performed using BioPharma Finder 4.0. All 
materials and equipment were supplied by Thermo Fisher Scientific 
unless otherwise stated. 
2.6. In vitro cell based assay for recombinant TGM1 bioactivity 
2.6.1. TGF-β bioassay 
The TGF-β bioassay (MFB-F11) developed by Tesseur et al. (2006) 
was performed as previously described (Smyth et al., 2018). Briefly, 
confluent MFB-F11 cells were added to each well of a 96-well 
round-bottomed plate. Wild type algal proteins or log dilutions (start-
ing at 100 ng⋅mL-1 of purified proteins such as HEK293T-expressed 
TGM1 (expressed and purified as previously described (Johnston 
et al., 2017)) or algal-expressed TGM1/TrTGM1 were then added to 
each well in a volume of up to 50 µL and incubated for 24 h at 37 ◦C in 
an atmosphere of 5% CO2. Subsequently, 20 µL of supernatant was 
aspirated from each well, added to an ELISA plate (NUNC) with 180 µL 
of reconstituted Sigma FastTM p-nitrophenyl phosphate substrate and 
incubated at RT in the dark for up to 4 h. Plates were read on at 405 nm 
on an Emax precision microplate reader (Molecular Devices). All con-
ditions were set up in duplicate and repeated at least twice. 
2.6.2. Foxp3+ Treg induction assay 
As described previously (White et al., 2021), a single cell suspension 
was prepared from the spleens of naïve Foxp3-GFP BALB/c transgenic 
mice (Fontenot et al., 2005), with contaminating red blood cells 
removed by resuspending the cells from one spleen in 2 mL of red blood 
cell lysis buffer (Sigma) and incubating at RT for 2 min. Cells were then 
washed and resuspended in RPMI medium supplemented with 
2 mM L-glutamine (Gibco), 100 U⋅mL-1 penicillin (Gibco), 100 μg⋅mL-1 
streptomycin (Gibco), 10% heat-inactivated fetal calf serum (FCS) 
(Gibco), and 1x MEM non-essential amino acid solution (Gibco). CD4+ T 
cells were enriched by magnetic sorting using the mouse naive CD4+ T 
cell isolation kit (Miltenyi 130-104-453) on an autoMACS Pro Separator 
(Miltenyi) as per manufacturer’s instructions. Cells were cultured at 
4 × 105 per well in flat-bottomed 96-well plates (Costar) pre-coated 
with 10 µg⋅mL-1 of anti-CD3 (clone 145-2C11; Invitrogen) with the 
addition of IL-2 (Miltenyi) at a final concentration of 400 U⋅mL-1 and 
with or without retinoic acid (Sigma) at a final concentration of 1 nM. 
Purified mammalian TGF-β (Peprotech), HEK293T expressed TGM1 
(expressed and purified as previously described, (Johnston et al., 2017)) 
or algal TGM1/TrTGM1 proteins were added at a concentration of 
20–100 ng⋅mL-1 and cells cultured at 37 ◦C in 5% CO2 for at least 72 h 
before being removed for flow cytometric analysis. All conditions were 
set up in triplicate and repeated at least twice. 
2.7. Flow cytometric analysis 
For viability staining, LIVE/DEAD® fixable blue (Life Technologies) 
was diluted to 1:1000 in PBS; 100 µL was added to each sample of cells, 
which were then incubated in the dark for 20 min at 4 ◦C and washed 
twice in FACS buffer. To prevent non-specific antigen binding, cells were 
incubated with 50 µL of polyclonal IgG (Sigma) (diluted 1:50 in FACS 
buffer) for 10 min at 4 ◦C and then washed twice in FACS buffer. Cells 
were surface stained with anti-CD3-BV711 (17A2, Biolegend), anti-CD4- 
PerCP/Cy5.5 (GK1.5, BioLegend) and anti-CD25-BV650 (PC61, Bio-
legend) to a total volume of 50 µL (diluted 1:200). Separate Foxp3 
staining was not always required as cells were from Foxp3-GFP trans-
genic mice however; to assess transcription factor expression, cells were 
stained with anti-Foxp3-eF450 (FJK-16s, eBioscience) and anti-RORγt- 
PE (Q31–378, BD Biosciences), both at 1:100 dilution, using the Tran-
scription Factor Staining Buffer set (eBioscience) and following manu-
facturer’s instructions. Single stain controls were individually added to 
one drop of UltraComp eBeads (eBioscience). Samples were incubated 
for 20 min at 4 ◦C, washed twice in FACS buffer and then resuspended in 
200 µL FACS buffer. All samples were acquired on a BD Biosciences 
Celesta and analyzed using FlowJo software (Tree Star). 
2.8. Animal models 
Female 6–8 week old C57BL/6J mice were purchased from Envigo 
(Huntingdon, UK) and housed in specific pathogen-free conditions and 
acclimatized in the animal unit for at least 1 week after arrival before 
experimental models were set up. All animal work was approved by the 
Ethical Review Board of the University of Glasgow and procedures were 
performed under a UΚ Home Office licence. 
2.8.1. Mouse feeding trial 
For initial evaluation of algal expressed TGM1 on mouse health and 
whether it would be tolerated/remain active after being ingested, we 
added algal expressed recombinant TGM1 protein directly to drinking 
water and allowed mice to drink ad libitum. Body weight and food/ 
water intake of the mice were monitored daily. For the control group, 
WT C. reinhardtii algal proteins or PBS/ 2% (v/v) glycerol were added to 
drinking water at the same volume and timing as the algal TGM1. Mice 
were sacrificed and isolation of lymphocytes from the Peyer’s patches 
(Mosconi et al., 2015), mesenteric lymph nodes (MLNs) (White et al., 
2021) lamina propria of small (Webster et al., 2020) and large (Clay 
et al., 2020) intestines were analyzed by flow cytometry. 
2.8.2. DSS colitis model 
The dextran sodium sulfate (DSS) chemical model of mouse model of 
colitis (Chassaing et al., 2014) was selected to determine the effects of 
algal expressed TGM1 in a murine model of acute colitis. Dextran so-
dium sulfate (36,000–50,000 MW, MP Biomedicals, Santa Ana, Cali-
fornia, USA) was added to the drinking water at 2% (w/v) for a total of 4 
days to disrupt the gut mucosal barrier, resulting in acute colitis. Mice 
were then given normal drinking water for the remainder of the 
experiment in order to monitor weight recovery. C. reinhardtii expressed 
TGM1 (ammonium sulfate precipitated from the supernatant) was also 
added to the drinking water initially throughout the 4-day DSS admin-
istration and for an additional 3 days (equaling a total of 7 days of algal 
TGM1 administered to the mice). 
Mice were weighed and scored daily for the entirety of the experi-
ment using a Disease Activity Index (DAI) matrix which comprised of 
scores out of 4 for % weight loss, blood, stool consistency and general 
appearance. Each day scores for each parameter were summed to give a 
DAI total out of 16 for each mouse. Animals were euthanized if they lost 
greater than 20% of their initial weight. Peyer’s patches and mesenteric 
lymph nodes were isolated for analysis by flow cytometry. 
2.9. Statistical tests 
Graphs and statistics were analysed using Prism (GraphPad, San 
Diego, California, USA). Shown are the means ± standard error (SEM), 
and one-way or two-way ANOVA or t-tests (paired or unpaired) were 
used where appropriate, with non-parametric Kruskal-Wallis tests being 
applied if data were not normally distributed. *P < 0.05. 
3. Results 
3.1. Expression and glycan analysis of C. reinhardtii expressed TGM1 
To express recombinant forms of the parasite TGF-β mimic TGM1 
and TrTGM1 using C. reinhardtii, we chose to utilize a vector (pBR9) that 
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would insert the gene cassette into the nucleus and secrete the recom-
binant protein continuously under light conditions (Fig. 1 A). Our 
strategy of expression included screening recombinant algae for high- 
expressing clones by a modified dot-blot assay, and purification of 
TGM1 proteins via a FLAG-tag suitable for antibody affinity chroma-
tography (Fig. 1 B). This allowed us to test algal expressed TGM1 
functionally, comparing it to the mammalian (HEK293T) expressed 
TGM1. 
For both constructs, single bands were detected in the algal super-
natant by anti-FLAG Western blot (Fig. 1 C). Quantification of the re-
combinant TGM1 against FLAG standard showed that the recombinant 
protein accumulated to approximately 5% of total soluble protein in the 
supernatant (Fig. 1 D, SupplementaryTable S1). Algal TGM1 was affinity 
purified using anti-FLAG M2 affinity resin, and the TGM1 amino acid 
sequence was confirmed using mass spectrometry (Supplementary 
Fig. 2A). 
We next assessed the level of glycosylation of the recombinant TGM1 
expressed by C. reinhardtii, as potential modification with plant-specific 
glycans, including core β1,2-xylose and α1,3-fucose, are reported to 
cause immunogenicity of recombinant proteins and evoke human anti-
body responses (Bardor et al., 2003). We subjected FLAG-purified algal 
TGM1 to digestion with PNGase F and Endoglycosidase H. Only PNGase 
F appeared to show minor changes to the FLAG-purified algal TGM1 
shown by the slight laddering of the protein on SDS-PAGE analysis after 
digestion (Supplementary Fig. 2B). Algal TGM1 was subjected to further 
glycosylation analysis by mass spectrometry, identifying 4 sites of 
N-glycosylation, and 1 of O-glycosylation (Supplementary Table S1); 
one potential N-glycosylation site (N-318 of the mature protein, Sup-
plementary Fig. 2) was not utilized. Although two previous studies 
found that 10–20% of glycosylated cellular proteins from C. reinhardtii 
carried one or two xylose additions to the mature oligomannoside chain 
(Lucas et al., 2020; Mathieu-Rivet et al., 2013), we could not detect any 
xylosylation of the recombinant TGM1 protein. In addition, we did not 
detect plant specific core α1,3-fucose on recombinant TGM1, consistent 
with this modification occurring in a core xylose-dependent manner 
(Oltmanns et al., 2019). Overall, only mammalian-like N-glycans were 
detected by our mass spectrometry analysis, and the PNGase F digestion 
(Supplementary Fig. 2B) indicated that their abundance was at a very 
low level. 
3.2. Bioactivity of TGM1 expressed in recombinant algae 
We next tested FLAG-purified recombinant TGM1 and TrTGM1 
produced in C. reinhardtii in two in vitro assays, a TGF-β reporter bioassay 
using MFB-F11 cells in which Smad signaling drives plasmid-encoded 
secretory alkaline phosphatase (Tesseur et al., 2006), and a Treg in-
duction assay in which naive Foxp3-negative mouse splenocytes from 
transgenic mice encoding a Foxp3-GFP fusion protein, are induced to 
express Foxp3-GFP (White et al., 2021). In the reporter assay, the 
algal-expressed cytokines showed bioactivity (Fig. 2 A), while wild-type 
algal products showed no effects (Supplementary Fig. 3 A). We noted, 
however, that the full-length algal TGM1 was approximately ten-fold 
less potent than the equivalent expressed in mammalian HEK293T 
cells. Nevertheless, at higher concentrations, algal TGM induced a 
stronger signal than even mammalian TGF-β. In addition, we found that 
the truncated TGM-1, lacking domains 4 and 5, was significantly weaker 
than the full-length expressed in the same algal system when tested in 
the MFB-F11 system, although at the highest concentrations it was able 
to equal the signal induced by the mammalian cytokine. 
We next evaluated whether algal-produced TGM1 proteins could 
induce Foxp3+ Treg cells from naïve pre-sorted Foxp3-negative CD4+ T 
cells. Cell cultures were treated with mammalian TGF-β, HEK293T- 
expressed TGM1, or FLAG-affinity-resin purified algae TGM1, together 
with the growth factor IL-2. Three days later, flow cytometry was used to 
identify induced Foxp3-GFP+ Treg cells (Fig. 2 B). In this system, both 
algal recombinant TGM1 and TrTGM1 proteins were able to induce 
Foxp3 to similar percentages as compared to TGF-β, and mammalian 
expressed TGM1, with the induction level being well above the back-
ground signal for the control group incubated with IL-2 alone (Fig. 2 C). 
Because retinoic acid (RA) is a known enhancer of Foxp3 induction, 
similar assays were conducted with and without RA, but we found no 
significant increase in its presence with the different TGM preparations 
(Supplementary Fig. 3B). 
3.3. Increase in mucosal Treg cell numbers following oral delivery of 
TGM1 to mice 
We then explored whether purified algal TGM1 could be fed and 
tolerated by mice and if so, could induce any immunological changes in 
intestinal tissues. In view of the lower potency and reduced quantities 
available of the truncated TGM1 protein, these studies focused on the 
full-length construct. We opted to administer TGM1 by addition of the 
whole algal secreted products to drinking water (at 100 µg⋅mL-1 TGM1 
within a total of 5.2 mg⋅mL-1, Supplementary Table S1) to provide car-
rier protein, and allow comparison with wild-type algal secretions. We 
then monitored water and food intake, and body weights, over time 
(Supplementary Fig. 4). 
Water intake was first ascertained and found to increase marginally 
above the average mouse consumption of 5 mL per day (indicated on 
Supplementary Fig. 4 A); this equates to mice receiving approximately 
0.5 mg of the algal TGM1 per day. Control mice received water with an 
equivalent concentration of WT algal secreting proteins including a 
matching volume of PBS/2% glycerol used in adding TGM1 to drinking 
water. Over the course of an 8-day period, there was no significant 
difference measured between the control group with WT algae and 
group receiving the algal TGM1 water, with respect to water or food 
intake (Supplementary Fig. 4A, B) or weight (Supplementary Fig. 4C) 
indicating that algal TGM1 consumed in drinking water showed no 
detrimental effects on appetite or body weight. 
At day 8, mucosal tissues (Peyer’s patches, mesenteric lymph nodes, 
small intestine, colon,) were harvested and cells were isolated, 
enumerated and subjected to flow cytometric analysis (Fig. 3 A). Peyer’s 
patches are the specialized structures in the small intestinal epithelium 
that act as the first-line lymphoid organ for mucosal immune system, in 
which lymphocytes activated by epithelial dome microfold (M) cells that 
transport antigens from the intestinal lumen (Da Silva et al., 2017). We 
noted with interest that both total cell counts, and the numbers of 
Foxp3+ Tregs, showed substantial increases in mice receiving TGM 
(Fig. 3 B, C), although the frequency of Tregs within the total pop-
ulations showed little change. Broadly similar patterns were observed in 
the mesenteric lymph nodes (MLNs, Fig. 3 D, E), and in intestinal tissue 
preparations from the small intestine (Fig. 3 F, G) and large intestine 
(Fig. 3 H, I), although in the latter case total cell numbers declined 
slightly, resulting in an overall increase in Treg proportions. 
3.4. Orally delivered algal TGM1 protects mice from DSS colitis weight 
loss 
To investigate anti-inflammatory effects of algal TGM1 in an in vivo 
mouse model of immunopathology, we used dextran sodium sulfate 
(DSS), a chemical to induce mucosal epithelial damage and disrupt 
mucosal barrier function (Chassaing et al., 2014). A percentage of 2% 
DSS (weight/volume) was added to the drinking water, resulting in an 
acute colitis, and the water for the algal TGM group contained 
100 µg⋅mL-1 TGM1 in addition to DSS. Mice were then allowed to drink 
freely from the DSS water for a 4 day period followed by a recovery 
period of 3 days on either standard drinking water (control group) or 
drinking water plus 100 µg⋅mL-1 TGM1 (algal TGM1 group), and an 
additional 7 days on standard drinking water to allow for mucosal repair 
(Fig. 4 A). Control mice were given the equivalent volume of wild-type 
algal proteins or diluent (1 x PBS/ 2% glycerol) in place of algal TGM1. 
Each mouse was weighed and scored daily to determine if algal TGM1 
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Fig. 2. FLAG-purified algal TGM1 and 
its bioactivity on TGF-β-responsive cell 
assays. A. MFB-F11 TGF-β receptor 
binding assay. MFB-F11 cells encode a 
Smad-responsive reporter construct 
which induces secretion of alkaline 
phosphatase following ligation of the 
TGF-β receptors; alkaline phosphatase 
is detected by addition of p-nitrophenyl 
phosphate substrate generating a color 
reaction. Cells were incubated with 
mammalian TGF-β, HEK293 expressed 
TGM1, οr algal secreted TGM1 / 
ΤrTGM1 at the indicated concentra-
tions and separately for 24 h, before 
recovery of supernatants for enzyme 
assay with p-nitrophenyl phosphate 
substrate. Data represent one of two 
similar experiments. B. Naïve T cells 
from transgenic mice encoding a 
Foxp3-GFP fusion protein (Fontenot 
et al., 2005) respond to TGF-β receptor 
ligation by expression of GFP that is 
detected by flow cytometry. Induction 
of primary mouse splenic CD4+ T cells 
to Foxp3-GFP expression. Data repre-
sent one of two similar experiments. C. 
Representative flow cytometry plots of 
Foxp3-GFP reporter T cells treated with 
TGF-β or TGM1 from mammalian 
(HEK) or algal (A-TGM) expression 
systems, together with IL-2. Control 
cultures received IL-2 alone. Forward 
Scatter (FSC-H) and Foxp3 expression 
and are plotted on the X and Y axes, 
with the same gate for positive cells for 
all samples.   
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mitigated the weight loss effect of DSS. 
All DSS mice started losing weight after administration of DSS, 
however mice administered algal TGM1 were protected from dramatic 
weight loss during DSS treatment and returned to their weight levels as 
measured before DSS treatment (Fig. 4 B). Compared to mice given DSS 
alone, the group also receiving wild-type algal proteins showed no 
protection, and for clarity data from this group are not shown. In the 
absence of algal TGM1, mice suffered a 20% weight loss 3–4 days after 
DSS administration while the weight loss of DSS + algal TGM1 group 
was only 10% in the same time window. In addition, mice not receiving 
TGM1 could not fully recover their weight loss, and continued to exhibit 
a 10% deficit after switching back to normal drinking water (Fig. 4 B). In 
parallel with attenuated weight loss, algal TGM1 also ameliorated dis-
ease symptoms accompanying DSS administration, reaching a lower 
severity and returning closer to baseline more quickly (Fig. 4 C). Taken 
together, these results indicate that algal TGM1 is effective at protecting 
mice from DSS-induced intestinal injury and weight loss. 
DSS-induced intestinal inflammation is known to provoke lymph-
adenopathy with significant increases in the size, weight, and cellular 
content of the mesenteric lymph nodes (MLNs) (Rehal et al., 2018). 
Fig. 3. Effect of algal TGM1 on mucosal immune cell populations. A. Experimental design for algal TGM1 feeding trial. B–I. Cell counts and Foxp3+ Treg numbers in 
intestinal tissues following feeding of WT algal proteins or algal-expressed TGM1, in the Peyer’s Patches (B, C), Mesenteric Lymph Nodes (D, E), Small Intestine (F, G) 
and Colon (H, I). Bars represent means and standard errors, with data from individual mice shown as solid symbols. Data represent one of two similar experiments. 
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Fig. 4. Amelioration of in vivo DSS mouse colitis with orally administered algal TGM1. A. Experimental design for DSS mouse feeding trial. DSS was fed to mice in the 
drinking water for 4 days with additional algal TGM1, followed by 3 days of standard drinking water with algal TGM1. The mice were allowed to recover for a further 
7 days with standard drinking water only. B, C. Course of colitis in mice receiving DSS in drinking water, measured by (B) Weight change, and (C) Disease Activity 
Scores, in mice fed with algal TGM1, and controls receiving DSS alone. D–G. Total cells and Foxp3+ Treg numbers in MLNs (D, E) and Peyer’s Patches (F, G) counted 
by flow cytometry. Bars represent means and standard errors, with data from individual mice shown as solid symbols. Data is from a single experiment. 
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Consistent with this previous work, we also found that total MLN cell 
numbers were greatly increased in mice treated with DSS, but remained 
at normal levels in the algal TGM recipients (Fig. 4 D). MLN Treg 
numbers were not higher in TGM-treated mice (Fig. 4 E) which may 
reflect more intense inflammation in the DSS alone animals. Interest-
ingly, DSS treatment reduced Peyer’s patch numbers (Fig. 4 F, G) 
although not in those mice receiving TGM, suggesting a protective ef-
fect. We also investigated stimulation of RORγt+ T cells, which are 
associated with gut inflammation and increases permeability of the 
epithelial barrier. There was an increase in all DSS-treated mice seen in 
the MLN (Supplementary Fig. 5B) but not the Peyer’s patches (Supple-
mentary Fig. 5C). 
4. Discussion 
Immuno-modulatory parasites are increasingly recognized as trea-
sure chests of novel, biologically active products with therapeutic po-
tential, particularly for inflammatory disorders which are increasingly 
prevalent in industrialized societies (Johnston et al., 2009; Kahl et al., 
2018; Maizels et al., 2018). Among the most severe of these “diseases of 
modernity” are inflammatory bowel diseases, for which no curative 
therapy is yet available (Kaser et al., 2010). The discovery of the im-
mune suppressive protein, TGM1, which mimics TGF-β, from a helminth 
parasite which itself can suppress intestinal inflammation (Leung et al., 
2012), led us to test the ability of recombinant TGM1 to inhibit in-
flammatory bowel disease in the well-characterized mouse model of 
DSS. Because the parasite, H. polygyrus, resides in the intestinal lumen, 
we reasoned that oral delivery would replicate its natural pathway of 
host modulation; and to test this hypothesis, we produced quantities of 
the TGM1 protein in the alga C. reichardtii. 
Expression of recombinant proteins in algae has been reported to be a 
cost-effective method to produce protein biologics, including human 
therapeutics such as antibodies, growth hormones, cytokines, and vac-
cines (Gimpel et al., 2015; Gregory et al., 2013; Patra et al., 2015; Rasala 
et al., 2012; Ravi et al., 2018; Tran et al., 2009). Algae have also been 
shown to be an effective vehicle to deliver vaccines (Gregory et al., 
2013) and recombinant therapeutic proteins (Barrera et al., 2015) to the 
gut, as C. reinhardtii has been granted GRAS status by the FDA and is safe 
to consume (Fields et al., 2020). We therefore tested expression of TGM1 
in this expression system and found that it produced sufficient quantities 
of soluble, mature recombinant TGM1 protein. We then used two 
established assays for TGF-β function which confirmed fully functional 
properties for the recombinant TGM1, including the induction of the 
Foxp3+ phenotype of immunosuppressive regulatory T cells (Tregs). We 
noted that algal TGM1 required a higher concentration for equivalent 
effect to TGM1 produced in mammalian cells, but that is nevertheless 
reached a greater maximum signal than did TGF-β itself. 
To evaluate the safety and physiological effect of algal TGM1 at 
steady state, it was administered to mice in the absence of any other 
intervention. No adverse effects were found, and there was a generalized 
enhancement of immune cell numbers, including Tregs, which was most 
marked in the Peyer’s patches, the localized immune structures in the 
small intestinal wall that serve as the primary interface between luminal 
contents and the mucosal immune system. 
We then tested TGM1 in the DSS induced model of colitis, in which 
mice exhibit immunopathogenic phenotypes including weight loss, 
diarrhea and rectal bleeding, resembling clinical symptoms of human 
disease (Okayasu et al., 1990; Wirtz et al., 2007). Along with the 
destruction of mucosal layer by DSS, commensal bacteria can cross the 
impaired epithelial barrier, stimulating the intestinal immune system to 
secrete pro-inflammatory cytokines and triggering inflammation. One 
corollary of intestinal inflammation is enlargement of the mesenteric 
lymph nodes which we observed were greatly increased in DSS-treated 
mice but not in those also receiving algal-expressed TGM orally. This 
suggests that TGM1 is able to reduce the inflammatory response of im-
mune cells in this model. 
Although TGM1 given to mice at steady-state tended to increase Treg 
numbers, a different outcome was observed in the DSS colitis model. 
One possibility is that inflammation itself elicits an influx of Tregs, such 
that at certain times they may be more abundant than in non-diseased 
cases; in IBD patients for example there are fewer circulating Tregs, 
but more in inflamed mucosal tissues (Maul et al., 2005; Wang et al., 
2011). An alternative explanation is that the disease suppresses the de 
novo (TGF-β-dependent) induction of Tregs, for example through 
increased inflammatory cytokine production and/or loss of dendritic 
cell subsets able to drive Treg expansion (Boschetti et al., 2017). It will 
be important in future studies of TGM1 modulation to tease out its ef-
fects on dendritic cells which play critical roles in driving and balancing 
intestinal inflammation (Hart et al., 2005). 
Over recent years, a number of potential new targets for IBD thera-
pies have been explored. For example, DCs and macrophages in IBD 
patients produce a higher level of activated IL-1; unfortunately however, 
antibody against IL-1 has no benefit for IBD treatment (Kojouharoff 
et al., 1997). Similarly, a monoclonal antibody targeting IFN-γ had no 
effect on Crohn’s disease patients (Reinisch et al., 2006). In the case of 
UC, patients express a more Type 2 profile (Fuss et al., 1996; Heller 
et al., 2005; Neurath, 2014), but anti-IL-13 antibody tralokinumab was 
not reported to have shown great clinical activity in patients with UC 
(Danese et al., 2015). For patients with either Crohn’s disease or UC, 
Th17 cells are abundant in inflamed intestine terminal ileum and pro-
duce IL17A, IL17F, IL26 and IFNγ. Nevertheless, treatment of secuki-
numab, an antibody to IL17A, was ineffective for Crohn’s disease and 
had severe side effects (Hueber et al., 2012). The most effective strategy 
to target pro-inflammatory cytokine is antibody against TNF which 
unfortunately is not effective for patients with few immune cells 
expressing membrane-bound TNF (Wong et al., 2008). 
In contrast, treatment with recombinant anti-inflammatory cyto-
kines has not been widely reported in IBD patients. Here we show for the 
first time that an algal produced TGF- β mimic, TGM1, acts in a similar 
manner to mammalian expressed TGM1 and limits disease intensity and 
lymph node inflammation when given orally in mouse model of colitis. 
In the case of TGF-β, caution has been expressed as the mammalian 
cytokine is associated with Th17 differentiation when IL-6 is present in 
vitro (Veldhoen et al., 2006). However, recently TGF-β has been 
observed to be associated with a non-inflammatory Th17 subset (Lee 
et al., 2020), and our own recent work demonstrates that TGM1 is 
effective in inducing Foxp3 expression in human Th17 memory cells 
(Cook et al., 2021) In addition, with respect to concerns that TGFβ 
promotes tissue fibrosis, TGM1 has been shown to be significantly less 
fibrogenic than mammalian TGF-β (Johnston et al., 2017). 
In conclusion, among a number of potential therapeutic cytokine 
therapy strategies, recombinant algal TGM1 offers several advantages 
including the oral mode of delivery, allowing direct action on inflamed 
mucosal surfaces while minimizing any systemic off-target effects. It is 
also very economical, compared to the cost of anti-TNF therapy and 
limited efficiency of other anti-inflammatory cytokines. It may also be 
beneficial to identify if recombinant algal TGM1 can be combined with 
other therapeutics, perhaps also expressed in algae, or antibodies 
against other immunomodulatory cytokines (for example TNF) which 
may further increase their therapeutic efficacy for patients with diverse 
immunopathological backgrounds. 
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